Go Back This article was viewed 42 times

Editorial


Nanobyte

Radhika A. Vaishnav
Department of Clinical Research, Vadodara Stroke Center, Director, Natureka Life Sciences, Vadodara, Gujarat, India
Corresponding Author:

Radhika A. Vaishnav

Department of Clinical Research, Vadodara Stroke Center, Director, Natureka Life Sciences, Vadodara, Gujarat, India
E-mail: radhikavaishnav@gmail.com

Corresponding Author:

Radhika A. Vaishnav

Department of Clinical Research, Vadodara Stroke Center, Director, Natureka Life Sciences, Vadodara, Gujarat, India
E-mail: radhikavaishnav@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20183224

ABSTRACT


An unintended effect of CRISPR-Cas-9 gene therapy may be the natural selection of p53-deficient cells. While this was unexpected, it highlights the need for continued basic research and carefully designed clinical trials to evaluate the mechanism and safety of this outcome.
Keywords: Gene editing, p53, Tumor suppressor, Side effects, CRISPR-Cas9